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Abstract
Background: Valganciclovir, the oral prodrug of ganciclovir, has been demonstrated equivalent to iv ganciclovir for
CMV disease treatment in solid organ transplant recipients. Variability in ganciclovir exposure achieved with
valganciclovir could be implicated as a contributing factor for explaining variations in the therapeutic response.
This prospective observational study aimed to correlate clinical and cytomegalovirus (CMV) viral load response
(DNAemia) with ganciclovir plasma concentrations in patients treated with valganciclovir for CMV infection/disease.
Methods: Seven CMV D+/R- transplant recipients (4 kidney, 2 liver and 1 heart) were treated with valganciclovir
(initial dose was 900-1800 mg/day for 3-6.5 weeks, followed by 450-900 mg/day for 2-9 weeks). DNAemia was
monitored by real time quantitative PCR and ganciclovir plasma concentration was measured at trough (Ctrough)
and 3 h after drug administration (C3h) by HPLC.
Results: Four patients presented with CMV syndrome, two had CMV tissue-invasive disease after prophylaxis
discontinuation, and one liver recipient was treated pre-emptively for asymptomatic rising CMV viral load 5 weeks
post-transplantation in the absence of prophylaxis. CMV DNAemia decreased during the first week of treatment in
all recipients except in one patient (median decrease: -1.2 log copies/mL, range: -1.8 to 0) despite satisfactory
ganciclovir exposure (AUC0-12 = 48 mg·h/L, range for the 7 patients: 40-118 mg·h/L). Viral clearance was obtained
in five patients after a median of time of 34 days (range: 28-82 days). Two patients had recurrent CMV disease
despite adequate ganciclovir exposure (65 mg·h/L, range: 44-118 mg·h/L).
Conclusions: Valganciclovir treatment for CMV infection/disease in D+/R- transplant recipients can thus result in
variable viral clearance despite adequate ganciclovir plasma concentrations, probably correlating inversely with
anti-CMV immune responses after primary infection.
Background
Cytomegalovirus (CMV) used to rank first as a cause for
morbidity and mortality among solid organ transplants
(SOT) recipients [1]. CMV disease can be prevented
either by CMV prophylaxis or pre-emptive treatment
guided by CMV viral load monitoring [1]. CMV-serone-
gative recipients who receive a transplant from a CMV-
positive donor (D+/R-) are at highest risk of developing
late CMV disease despite prophylaxis [2] with an
incidence up to 43% [3]. Valganciclovir, the ester pro-
drug of ganciclovir, is currently used for CMV prophy-
laxis [4] and has been demonstrated equivalent to iv
ganciclovir for CMV disease treatment in SOT recipi-
ents [5]. As ganciclovir plasma levels were not reported
in most treatment studies using valganciclovir, variability
in ganciclovir exposure achieved with this oral prodrug
(e.g. due to malabsorption) could be imagined as a con-
tributing factor partly explaining variations in the thera-
peutic response. The present prospective study aimed at
describing the clinical and virological outcome (CMV* Correspondence: pascal.meylan@chuv.ch
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viral load response) along with ganciclovir plasma con-
centration exposure in SOT patients receiving valganci-
clovir treatment for CMV infection/disease.
Methods
Patients
The present consecutive series of patients presenting
CMV disease and treated with valganciclovir was
observed during a population pharmacokinetic study of
valganciclovir conducted at the University Hospital, Lau-
sanne, Switzerland, with the approval of the local ethics
committee [6]. Adult SOT recipients with either CMV
asymptomatic infection treated pre-emptively or with
CMV disease [7] receiving oral valganciclovir treatment
were enrolled after giving a written informed consent.
Valganciclovir therapeutic dosage for CMV infection
was 900 mg twice daily (adjusted to renal function
according to the manufacturer recommendations and
subsequently to ganciclovir blood levels) followed by a
maintenance therapy (900 mg once daily with similar
adjustment). Ganciclovir levels were measured weekly at
trough (Ctrough) and 3 hours after oral administration
(C3 h) during treatment along with CMV viral load. The
duration of the therapy was left to the decision of the
physician in charge of the patient. In case of recurrence
of CMV disease (defined as second episode after first
CMV disease symptoms resolution), valganciclovir was
reintroduced at therapeutic dosage. Kidney and cardiac
transplant recipients received induction therapy with
basiliximab (n = 3) or thymoglobuline (n = 2). The
maintenance immunosuppressive regimen included pre-
dnisone in all patients associated with either tacrolimus
(in 5 patients) or cyclosporine (in 2 patients), and myco-
phenolate mofetil (in 4 patients), mycophenolate sodium
(in 1 patient) or azathioprine (in 1 patient).
Ganciclovir plasma level and pharmacokinetic profile
Plasma ganciclovir concentrations were determined by
reverse-phase HPLC coupled with spectrofluorimetric
detection according to a validated method [8]. The cali-
bration curve was linear between 0.1 and 10 mg/L, the
inter-day coefficient of variation was lower than 3.5%
and the range of inter-day deviations comprised within
-0.4 to +1.4%.
Ganciclovir plasma concentration results were ana-
lysed in a population pharmacokinetic study in the
whole population of 65 transplant patients including
this subgroup along with a majority of patients receiving
valganciclovir for CMV prophylaxis. The analysis was
performed by non-linear mixed effect modelling using
the NONMEM® computer program. The structural
model was two-compartment with first-order absorp-
tion. Systemic clearance was markedly influenced by
GFR, sex and graft types. Body weight and sex influ-
enced central volume of distribution. There was no
difference in drug disposition between patients receiving
valganciclovir for prophylaxis versus therapy. Ganciclo-
vir exposure was evaluated by calculating the area under
the curve (AUC) for each individual and sampling occa-
sion, based on the subject-specific clearance value esti-
mated at the end of the population analysis (maximum
likelihood a posteriori Bayesian estimation) [6].
Virological and immunity monitoring
CMV viremia was measured in whole blood using a
CMV DNA real time quantitative PCR [9] with results
expressed in number of copies/mL (limit of quantifica-
tion: 1000 copies/mL, threshold of detection close to
100 copies/mL). DNAemia clearance was defined after
one negative PCR. Recurrence of CMV disease was
defined as reappearance in the blood of CMV DNA
accompanied by symptoms.
CMV and EBV antibody status of donor and recipient
were determined using commercialised kit. CMV speci-
fic and EBV specific T-cell response were assessed by
ELISPOT assays. (Additional file 1)
Mutations in the CMV UL97 kinase gene were looked
for in one patient. Part of the UL97 region covering
most of the known mutations associated with resistance
to ganciclovir (codons 437-609 [10,11]) was amplified by
PCR using CMV_UL97 M_F (TGCACGTTGGCC-
GACGCTAT: position 1308-1327 within the UL97 open
reading frame) and CMV_UL97 M_R (GCCGCCA-
GAATGAGCAGACA position 1837-1818 on the com-
plementary strand of the UL97 open reading frame).
(Additional file 1)
Results
Seven CMV D+/R- patients (4 kidney, 2 liver and 1
heart recipients) were treated with valganciclovir: 6 for
late-onset CMV disease (CMV syndrome n = 4 and
CMV tissue-invasive disease n = 2) and one pre-emp-
tively for CMV asymptomatic infection (n = 1) (Table
1). Treatment started between 1.4 and 21.5 months after
discontinuation of valganciclovir prophylaxis in 6
patients and 5 weeks after transplantation in the liver
recipient who was treated pre-emptively. Initial valganci-
clovir dose was 900-1800 mg/day adjusted to calculated
creatinine clearance for a median of 38 days (range: 20-
63 days), followed by maintenance therapy (450-900
mg/day for a median of 27 days, range: 0-62 days). Dur-
ing valganciclovir treatment, maintenance immunosup-
pressive regimen consisted in prednisone 5-15 mg per
day (depending on the time post-transplantation), in
tacrolimus (mean plasma trough levels between 6-10
μg/L) in 5 patients and cyclosporine (mean plasma
trough levels between 170-250 μg/L) in 2 patients.
Doses of mycophenolate mofetil were reduced in 4
patients (initially 1-2 grams per day to 0.5-1 gram per
day when valganciclovir was initiated and further
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stopped in 2 patients), as well as mycophenolate sodium
in 1 patient (360 mg per day then stopped) and
azathioprine in 1 patient (150 mg per day progressively
reduced over 2 months then stopped). Figures 1 and 2
show valganciclovir dosage, ganciclovir plasma levels
and CMV viral load over time for each patient.
Clinical symptoms resolved in all symptomatic
patients with a median of 14.5 days of treatment (range:
5-28 days). The median viral load decline in these 7
patients was -1.2 log copies/mL after 1 week of treat-
ment with a wide variation ranging from 0 to -1.8 log
copies/mL. Viral clearance was obtained in five patients
after a median time of 34 days (range: 28-82 days). In
one patient, CMV DNAemia remained detectable but at
a low level until lost of follow-up (48 days after 76 days
of valganciclovir treatment discontinuation). Two SOT
recipients (patients 4 and 7) developed 1-2 recurrent
CMV disease episodes (follow-up: 9 months, range: 4-21
months) (Table 1). Median baseline viral load was 5.0
log copies/mL (range: 3.2-5.1 log copies/mL) in 5
patients without recurrent episode and 3.9 and 6.3 log
copies/mL in patients with relapse. Median ganciclovir
Ctrough during induction treatment was 1.5 mg/L (range:
0.8-3.3 mg/L) and C3h 6.4 mg/L (range: 4.1-10.8 mg/L)
Figure 1 CMV treatment with valganciclovir in patients 1-6. valganciclovir dosage (red rectangle), ganciclovir plasma concentration (closed
white circle: concentration measured at trough, closed white triangle: concentration measured 3 h after last dose, red line: concentration
predicted by population pharmacokinetic model), CMV viremia (blue square and solid blue line) and symptoms period (blue diamond)
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in patients without relapse and 3.6 mg/L (range: 1.8-5.7
mg/L) and C3h 6.5 mg/L (range: 5.3-6.7 mg/L) in
patients with relapse, corresponding to ganciclovir expo-
sure of 43.8 mg·h/L (32.7-74.3 mg·h/L) and 65.3 mg·h/L
(44.3-117.9 mg·h/L), respectively. Overall, the median
viral load decline of the 10 treatment courses in these 7
patients was -1.0 log/week with a wide variation ranging
from 0 to -2.9 log/week.
Two patients had particularly complicate outcomes.
Patient 4 was treated with oral valganciclovir a second
time for a CMV syndrome 21 days after first therapy
cessation and a third time for a CMV colitis 45 days
after the second course discontinuation. CMV viremia
decreased by -1.1 log copies/mL after 14 days, -3.0 log
copies/mL after 15 days and -1.7 log copies/mL after 14
days during the first, second and third treatment,
respectively (Figure 1). Trough ganciclovir concentra-
tions and AUC determined during these two episodes
remained at the therapeutic range despite dose reduc-
tion while the patient renal function deteriorated. This
patient developed hepatitis with moderate hepatocellular
insufficiency during the second episode of CMV disease,
possibly related to high ganciclovir plasma levels, requir-
ing treatment interruption. Anti-CMV IgG measured
after the first and the second course of valganciclovir
showed a seroconversion after the second CMV disease
episode only (14 months after transplantation). CMV
specific T-cell response was not assessed. He developed
however a third episode of CMV disease. His condition
deteriorated due to cardiac decompensation and respira-
tory failure. He died from a septic shock and multi-
organ failure while the CMV viral load was decreasing.
Patient 7 had an unusual course upon treatment
initiation, his viral load first increasing by 1.2 log
copies/mL after 16 days of treatment and then decreas-
ing by -2.4 log copies/mL over the second week of treat-
ment even though ganciclovir plasma levels remained
stable. Median ganciclovir plasma levels and systemic
exposure (AUC) during induction treatment were 1.9
mg/L (range 1.8-2.6 mg/L) and 46.5 mg·h/L (range:
44.3-47.5 mg·h/L, 4 measures), respectively, thus show-
ing very little changes. Dose of mycophenolate mofetil
was reduced (1.5 g per day to 0.5 g per day) 5 days
before valganciclovir treatment initiation as leucopenia
was detected and stopped one week after valganciclovir
treatment initiation. Dose of prednisone was increase
from 5 mg per day to 10 mg and tacrolimus plasma
level were maintained at 8 μg/L. This patient developed
a second episode of CMV disease 62 days after first
treatment discontinuation. CMV viral load stabilized at
4 log copies/mL before valganciclovir treatment start
and became undetectable while on treatment (Figure 2).
UL97 mutations were searched by gene sequencing but
not detected. Anti-CMV IgM and IgG measured during
the first and the second CMV episodes revealing low
level of IgM from day 15 of first treatment course on
while IgG remained undetectable until 4 months after
the second treatment cessation (14.5 months after trans-
plantation). CMV specific T-cell response assessed by
ELISPOT assay after the first and second treatment
(about 7 and 10.5 months after transplantation) showed
low but rising numbers of IFN-g-producing CMV-speci-
fic cells. Interestingly, this patient D+/R- for EBV devel-
oped also a high EBV viral load and did not build an
EBV specific T cell response (Figure 2).
Figure 2 CMV prophylaxis and treatment with valganciclovir in
patient 7. valganciclovir dosage (red rectangle), ganciclovir plasma
concentration (closed white circle: concentration measured at
trough, closed white triangle: concentration measured 3 h after last
dose, red line: concentration predicted by population
pharmacokinetic model), CMV viremia (blue square and solid blue
line), symptoms period (blue diamond), EBV viremia (green triangle
and dotted green line), anti-CMV IgM and IgG (IgM: closed white
square and dotted blue line, IgG: blue circle and solid blue line),
anti-EBV IgM and IgG (IgM: closed white square and dotted green
line, IgG: closed green circle and solid green line), CMV specific T-
cell response and EBV specific T-cell response (Interferon-g, IF-g -:
negative; IF-g +: positive)
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Discussion
We report on 7 recipients D+/R- treated with valganci-
clovir for CMV late disease after prophylaxis (n = 6)
and pre-emptively for CMV infection (n = 1) with moni-
toring of CMV viral load and ganciclovir plasma level.
This small number of observations reflects the single
centre nature of our study and the rather good efficacy
of prophylaxis (which was prescribed to all patients
except to few liver transplant recipients), decreasing the
incidence of CMV disease among SOT recipients.
We observed a widely variable response with delayed
CMV viremia load decrease in 1/7 recipient and recur-
rent infection in 2/7 patients. The rate of CMV viral
load decrease after 1 week of treatment was in the range
of those reported with iv ganciclovir [12] or oral valgan-
ciclovir [12,13], but viremia clearance was lower in our
population including only D+/R- recipients. There was
absolutely no indication that this variable response
could be related to insufficient ganciclovir exposure, as
shown by the result of ganciclovir plasma level monitor-
ing revealing sufficient [14] or even rather higher con-
centrations in the patients with poor response.
Ganciclovir needs to be bio-activated in infected cells
into ganciclovir triphosphate to inhibit virus replication.
In the absence of available clinical samples containing
appropriate numbers of infected cells, ganciclovir plasma
concentration is the only measurable surrogate of the
actual active form concentration. Delayed viral clearance
or recurrent infection seems thus more likely related to
the absence of CMV cell-mediated immunity in a subset
of patients experiencing primary infection while on
immunosuppressive therapy [15]. However, the present
study was not designed to assess the cell-mediated spe-
cific response to CMV. Emery et al, by comparing CMV
replication dynamics in CMV-naïve and -experienced
hosts, demonstrated that a higher drug efficacy was
required to eliminate viral replication in non immune
liver transplant recipients [16]. Additionally it has been
shown that viral factors, such as infection with multiple
CMV glycoprotein B genotypes, may also influence the
response to antiviral therapy [17]. Interestingly, one
patient experienced simultaneous primary infection by
CMV and EBV, with delayed response to valganciclovir
treatment and recurrent CMV infection. CMV primary
infection has been reported to increase the risk of a
EBV related PTLD in high risk (D+/R-) EBV recipients
[18]. Conversely, one wonders whether EBV infection
could influence the course of CMV infection.
Conclusions
In conclusion, variable viral clearance could not be
explained by a lower ganciclovir exposure in valganci-
clovir-treated patients, but was probably related to the
immunological variability of seronegative recipients
undergoing primary infection early after transplantation
or after prophylaxis discontinuation or to viral factors.
Additional file 1: Supplementary material. Materials and methods for
the determination of CMV antibody status, the assessment of CMV
specific and EBV specific T-cell response and the detection of mutations
in the CMV UL97 kinase gene are described in more detail.
Click here for file
[ http://www.biomedcentral.com/content/supplementary/1471-2334-10-2-
S1.DOC ]
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